Kezar Life Sciences (KZR) Expected to Announce Quarterly Earnings on Thursday

Kezar Life Sciences (NASDAQ:KZR) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($2.56) per share for the quarter.

Kezar Life Sciences (NASDAQ:KZR) last released its earnings results on Tuesday, March 25th. The company reported ($2.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.71) by ($0.06). On average, analysts expect Kezar Life Sciences to post $-4 EPS for the current fiscal year and $-8 EPS for the next fiscal year.

Kezar Life Sciences Stock Performance

Shares of KZR opened at $4.38 on Thursday. Kezar Life Sciences has a 1 year low of $3.62 and a 1 year high of $9.18. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.65 and a quick ratio of 7.65. The stock’s fifty day moving average price is $5.04 and its two-hundred day moving average price is $6.27. The firm has a market cap of $32.00 million, a PE ratio of -0.33 and a beta of 0.61.

Wall Street Analyst Weigh In

Separately, William Blair reiterated an “outperform” rating on shares of Kezar Life Sciences in a research note on Friday, February 28th.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.